

Docket No.: REG 660AZ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: Not yet known

Group: Not yet known

Filing Date: Herewith

Examiner: Not yet known

Title: DCR5 Bone Affecting Ligand

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450.

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

(b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

or

(c) After (b) above, but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, the undersigned certifies as follows:

[] (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

[] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

or

[] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p);

or

[] (d) After (c) above, but on or before payment of the issue fee and the undersigned certifies as follows:

[] (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

[] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

and

[] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).

REQUEST FOR TRANSFER OF REFERENCE COPIES

[x] Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN 09/762,960, filed February 14, 2001, be transferred to the subject application for consideration by the Examiner

Fees

The fee required for the filing of this Information Disclosure Statement is estimated to be \$_____. Applicants hereby authorize such charge to Deposit Account number 18-0650. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-050.

Respectfully submitted
Linda O. Palladino
Linda O. Palladino
Reg. No. 45,636
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 660AZ
 Serial No. : Not yet known
 Applicant: : Economides, A. and Stahl, N.
 Date Filed : Herewith
 For : DCR5 BONE AFFECTING LIGAND
 Examiner : Not Yet Known
 Group Art Unit : Not Yet Known

15 September 2003

U.S. PATENT DOCUMENTS

Examiner Initials	Patent/ Publication Number	Patent/ Publication Date	Serial Number	Filing Date	Name
_____	_____	_____	60/097,296	8/20/98	Economides,A. & Stahl,N.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	Translation No
_____	WO98/33918	8/6/98	PCT	_____	_____	_____
_____	WO99/03996	1/28/99	PCT	_____	_____	_____
_____	WO99/06552	2/11/99	PCT	_____	_____	_____
_____	WO00/11163	3/2/00	PCT	_____	_____	_____

OTHER DOCUMENTS

Examiner Initials	Document Description
_____	NATURE, Bouwmeester, et al., 1996, "Cerebrus is a head-inducing secreted factor expressed in the anterior endoderm of Spemann's organizer," 382:595-601.
_____	SCIENCE, Lamb, T. M., et al., 1993, "Neural Induction by the Secreted Polypeptide Noggin," 262:713-718.
_____	CELL, Smith, W. C., et al., 1992, "Expression Cloning of noggin, a New Dorsalizing Factor Localized to the Spemann Organizer in Xenopus Embryos," 70:829-840.
_____	NATURE, Smith, W. C., et al., 1993, "Secreted noggin protein mimics the Spemann organizer in dorsalizing Xenopus mesoderm," 361:547-549.

_____ CELL, Zimmerman, L. B., et al., 1996, "The Spemann Organizer Signal noggin Binds and Inactivates Bone Morphogenic Protein 4," 86:599-606.

_____ CELL, Piccolo, S., et al., 1996, "Dorsoventral Patterning in Xenopus: Inhibition of Ventral Signals by Direct Binding of Chordin to BMP-4," 86:589-598.

_____ NATURE, Sasai, Y. et al., 1995, "Regulation of neural induction by the Chd and the Bmp-4 antagonistic patterning signals in Xenopus," 376:333-336.

_____ CELL, Sasai, Y., et al., 1994, "Xenopus chordin: A Novel Dorsalizing Factor Activated by Organizer-Specific Homeobox Genes," 79:779-790.

_____ ONCOGENE, Enomoto, et al., 1994, "Identification of human DAN gene, mapping to the putative neuroblastoma tumor suppressor locus," 9:2785-2791.

_____ JPN. J. CANCER RES., Ozaki, et al., 1996, "Cloning of Mouse DAN cDNA and its Down-regulation in Transformed Cells," 87:58-61.

_____ MOL CELL, Hsu, et al., 1998, "The Xenopus Dorsalizing Factor Gremlin Identifies a Novel Family of Secreted Proteins that Antagonize BMP Activities," 1:673-683.

_____ DEV GROWTH DIFFER, Minabe-Saegusa, C. et al., 1998, "Sequence and expression of a novel mouse gene PRDC (protein related to DAN and cerebrus) identified by a gene trap approach," 40:343-353.

_____ GENE, Holler, T.P., et al., 1993, "HIV1 integrase expressed in Escherichia coli from a synthetic gene," 136:323-328.

_____ GENE, Martin, S.L., et al., 1995, "Total synthesis and expression in Escherichia coli of a gene encoding human tropoelastin," 154:159-166.

_____ SCIENCE, Davis, S., et al., 1994, "Ligands for EPH-Related Receptor Tyrosine Kinases That Require Membrane Attachment or Clustering for Activity," 266:816-819.

EXAMINER
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:


Linda O. Palladino
Reg. No. 45,636
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400